Leerink Swann Defends Boston Scientific (BSX); Minor ICD Component Issue
Tweet Send to a FriendGet Alerts BSX Hot Sheet
Price: $9.40 --0%
Rating Summary:
8 Buy, 16 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 2 | New: 2
Rating Summary:
8 Buy, 16 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 2 | New: 2
Trade BSX Now!
Leerink Swann defends Boston Scientific (NYSE: BSX) this morning, maintaining an 'Outperform' rating and price target of $8.00.
Analyst, Rick Wise. said, "An April 2012 product advisory update to Boston Scientific’s PPR (Product Performance Report) public website highlights---what seems to us---a relatively minor product performance issue with the Cognis/Teligen family of ICDs. Specifically, in 26 out of 233,000 Cognis/Teligen ICD units implanted “an electrical component referred to as a ‘transformer’ has exhibited an identifiable pattern of malfunction…”. While the event rate is extremely low, the report notes that there have been four patients who felt a “sudden heating sensation at the implant site” and there has been one patient death.”"
Wise, defends the company, saying Cognis/Teligen is still very reliable, with the event rate being extremely low. Wise also feels the company is a turnaround story (which may take some time), but has the new/right management in place.
Note - shares dropped about 1.5% on the news around 9:50AM EST.
For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.
Shares of Boston Scientific closed at $5.94 yesterday, with a 52 week range of $5.01-$7.91.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Rick Wise. said, "An April 2012 product advisory update to Boston Scientific’s PPR (Product Performance Report) public website highlights---what seems to us---a relatively minor product performance issue with the Cognis/Teligen family of ICDs. Specifically, in 26 out of 233,000 Cognis/Teligen ICD units implanted “an electrical component referred to as a ‘transformer’ has exhibited an identifiable pattern of malfunction…”. While the event rate is extremely low, the report notes that there have been four patients who felt a “sudden heating sensation at the implant site” and there has been one patient death.”"
Wise, defends the company, saying Cognis/Teligen is still very reliable, with the event rate being extremely low. Wise also feels the company is a turnaround story (which may take some time), but has the new/right management in place.
Note - shares dropped about 1.5% on the news around 9:50AM EST.
For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.
Shares of Boston Scientific closed at $5.94 yesterday, with a 52 week range of $5.01-$7.91.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Goldman Sachs Upgrades Tanger Factory Outlet Centers (SKT) to Neutral
- UPDATE: Raymond James Downgrades Gevo, Inc. (GEVO) to Market Perform
Create E-mail Alert Related Categories
Analyst Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
